Streetbeat News

Price Targets

CPNG

Barclays analyst Jiong Shao has maintained an Overweight rating on Coupang (NYSE:CPNG) and raised the price target from $22 to $24.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:36 am

WHD

Barclays analyst David Anderson maintains an Equal-Weight rating on Cactus (NYSE:WHD) and raises the price target from $46 to $48.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:35 am

ARHS

Arhaus, Inc. (NASDAQ:ARHS) reported better-than-expected Q2 earnings, leading to an 8.7% increase in share price. The company also tightened its FY23 revenue guidance. Following the announcement, Telsey Advisory Group and Barclays raised their price targets on Arhaus.

Portfolio Pulse from Lisa Levin

August 10, 2023 | 11:34 am

BRBR

Barclays analyst Lauren Lieberman maintains an Overweight rating on BellRing Brands (NYSE:BRBR) and raises the price target from $41 to $43.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:29 am

ARMK

Barclays analyst Manav Patnaik maintains an Underweight rating on Aramark (NYSE:ARMK) and raises the price target from $36 to $38.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:29 am

OLPX

Barclays analyst Lauren Lieberman maintains an Underweight rating on Olaplex Hldgs (NASDAQ:OLPX) and lowers the price target from $3 to $2.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:27 am

JACK

Barclays analyst Jeffrey Bernstein has maintained an Equal-Weight rating on Jack In The Box (NASDAQ:JACK) but lowered the price target from $99 to $90.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:26 am

GRPN

Barclays analyst Trevor Young maintains an Underweight rating on Groupon (NASDAQ:GRPN) and raises the price target from $4 to $6.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:26 am

FATE

Barclays analyst Peter Lawson maintains an Overweight rating on Fate Therapeutics (NASDAQ:FATE) but has lowered the price target from $12 to $6.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:25 am

ARHS

Barclays analyst Seth Sigman has maintained an Overweight rating on Arhaus (NASDAQ:ARHS) and raised the price target from $12 to $14.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:24 am